Trial Profile
A clinical study of triple combinations to evaluate IPI-549 in combination with AB928 and AB122 in in triple negative breast cancer and ovarian cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2018
Price :
$35
*
At a glance
- Drugs Eganelisib (Primary) ; Etrumadenant (Primary) ; Zimberelimab (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Therapeutic Use
- 16 Nov 2018 New trial record
- 05 Nov 2018 According to an Infinity Pharmaceuticals media release, top line results from this study are expected in 2019.